drugset / Trial / NCT03841136
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen
Timeline
- Start
- 2019-04-01
- Primary completion
- 2019-12-01
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |